Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Michael Wysocki on Precision Molecular Imaging & PSMA PET Innovation: Blue Earth Diagnostics’ Vision for Personalized Prostate Cancer Care

Shots:  Blue Earth Diagnostics is advancing precision molecular imaging in prostate cancer through its F-18 PET imaging portfolio, with POSLUMA and Axumin designed to improve disease localization, support earlier clinical decision-making, and enhance physician confidence, particularly in patients experiencing biochemical recurrence.  At SNMMI 2026, the company presented new evidence highlighting POSLUMA's strong detection performance at low PSA levels, reduced urinary…
13 hours ago

Read more

NEWS

Philips Receives US FDA 510(k) Clearance for AI-Powered Spectral CT Verida System

Shots: The US FDA has granted 510(k) clearance to Philips for its Spectral CT Verida system, an AI-powered detector-based spectral CT platform for diagnostic imaging Verida integrates always-on spectral imaging with AI-based deep learning reconstruction to enhance image quality, reduce noise, and improve diagnostic precision across radiology, cardiology, and oncology applications The system enables simultaneous…
April 17, 2026

Read more

Intelerad
NEWS

GE HealthCare to Acquire Intelerad for $2.3B

Shots: GE HealthCare has entered into an agreement to acquire Intelerad, expanding its cloud-enabled & AI-powered solutions portfolio As per the deal, GE HealthCare will acquire Intelerad for a purchase price of $2.3B in cash; closing is expected in H1’26 Acquisition will add Intelerad’s cloud-enabled radiology & cardiology imaging platforms & outpatient enterprise workflow solutions…
November 21, 2025

Read more

VIEWPOINTS_Richard Stefanacci_2024
VIEWPOINTS

Neurogenerative Disorders Management: Richard Stefanacci of TauRx in an Enlightening Conversation with PharmaShots

Shots:  Richard Stefanacci, Chief Medical Officer at TauRx, sheds light on the anti-tau drug Hydronomethylthionine mesylate (HMTM), a potential oral treatment for patients with Alzheimer’s disease and mild cognitive impairment  While highlighting the positive results from the LUCIDITY P-III study, Richard speaks about bridging the gap in AD and MCI treatment by lowering the dependence…
March 18, 2024

Read more